TScan Therapeutics, Inc. Common Stock (TCRX) is a publicly traded Healthcare sector company. As of May 21, 2026, TCRX trades at $0.99 with a market cap of $65.35M and a P/E ratio of -1.05. TCRX moved +3.26% today. Year to date, TCRX is -4.37%; over the trailing twelve months it is -17.80%. Its 52-week range spans $0.88 to $6.23. Analyst consensus is strong buy with an average price target of $6.00. Rallies surfaces TCRX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies organizes TCRX SEC filing research, company disclosures, 10-K reports, 10-Q reports, and filing-driven context alongside market data, news, fundamentals, and AI research.
| Metric | Value |
|---|---|
| Price | $0.99 |
| Market Cap | $65.35M |
| P/E Ratio | -1.05 |
| EPS | $-0.96 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.23 |
| 52-Week Low | $0.88 |
| Volume | 6.39K |
| Avg Volume | 0 |
| Revenue (TTM) | $9.14M |
| Net Income | $-124.31M |
| Gross Margin | 0.00% |
6 analysts cover TCRX: 0 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.00.